American Journal of Psychiatry – Disclosure of Editors’ Financial Relationships

Facebooktwittergoogle_plusredditpinterestlinkedinmailFacebooktwittergoogle_plusredditpinterestlinkedinmail

American Journal of Psychiatry
Disclosure of Editors’ Financial Relationships
April 1, 2015

“The American Journal of Psychiatry is the most widely read psychiatric journal in the world. Published monthly, it is an indispensable journal for all psychiatrists and other mental health professionals who need to stay on the cutting edge of virtually every aspect of psychiatry. No other psychiatric journal reaches more psychiatrists with greater impact or immediacy than The American Journal of Psychiatry, the journal that the overwhelming majority of psychiatrists consider essential.”

Psychiatrist Agustus John Rush

Psychiatrist Agustus John Rush

Disclosure of Editors’ Financial Relationships

The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Robert Freedman, M.D, reports no financial relationships with commercial interests.

David A. Lewis, M.D., currently receives investigator-initiated research support from Pfizer and in 2012-2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, and Concert Pharmaceuticals.

Robert Michels, M.D., reports no financial relationships with commercial interests.

Daniel S. Pine, M.D., reports no financial relationships with commercial interests.

A. John Rush, M.D., has served as a consultant for Eli Lilly, Santium and Takeda; and has received compensation from Brain Resource, Inc., Guilford Press, Lundheck, and Medavante.

Susan K. Schultz, M.D., has received research support from the Alzheimer’s Disease Cooperative Study for projects conducted in partnership with Toyama Chemical Company and in partnership with Eli Lilly and Company.

Carol A. Tamminga, M.D., has received research support from Sunovion and travel funds from Autiphony Therapeutics and has served as a consultant for Astellas, Eli Lilly, Kaye Scholer LLC for Pfizer, and Lundbeck.